Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 3 1Phase 2/3 1

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Malignant Ascites 2Ovarian High Grade Serous Adenocarcinoma 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Paracentesis × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

NCT05998135 2025-09-11

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Emory University

Phase 2 Recruiting
28 enrolled
Gynecologic

Ovarian High Grade Serous Adenocarcinoma

NCT06266091 2025-07-20

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 2 Completed
115 enrolled

Malignant Ascites

NCT04032600 2020-12-08

ATLANTIS

Charite University, Berlin, Germany

Phase NA Completed
61 enrolled
Gynecologic

Ovarian Neoplasms

NCT02441140 2020-05-04

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Dana-Farber Cancer Institute

Phase NA Terminated
5 enrolled
Gynecologic

Ovarian Neoplasms

NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Neovii Biotech

Phase 2/3 Completed
258 enrolled
BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡